Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS
Content archived on 2024-05-07

The synthesis of the galbulimima alkaloids himgravine and himbacine - potential therapeutic agents for alzheimer's disease

Objective



In the last decades isolation and screening of natural products has become a very important factor in finding new therapeutic agents. During this project a synthesis for the Galbulimima Alkaloids Himgravine 7 and Himbacine 8 should be developed. These Alkaloids should stimulate the release of acethylcholin and due to the cholinergic hypothesis should alleviate the symptoms for Alzheimer's disease. A retrosynthetic approach, as illustrated in scheme 1, shows that suitable building blocks can be prepared starting with substrates from the chiral pool like amino acids, lactic acid 1 as well as heterocycles 6 by using various standard organic reactions (C-C coupling reactions, protection and deprotection of functional groups and stereoselective synthesis). Modern analytical methods like HPLC, GC, NMR-, IR- and Masspectrometrie will be used to identify the intermediates and products.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Call for proposal

Data not available

Funding Scheme

RGI - Research grants (individual fellowships)

Coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
EU contribution
No data
Address
South Parks Road
OX1 3QY OXFORD
United Kingdom
Total cost
No data

Participants (1)